Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Misoprostol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER3 known ✓ | P43115 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PGR | P06401 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PTGIR | P43119 | 9/20 | 0.61 |
| ▸ | PTGER2 | P43116 | 8/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.49 |
| ▸ | RARB | P10826 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Misoprostol SCHEMBL10328461 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL22039860 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL22381095 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL24176879 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL20646583 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL24176880 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL22381098 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL23352527 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL21423327 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB | |
| Misoprostol SCHEMBL13575775 | 1.00 | LMNA (1.00) | LMNAABCC4PGRALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| US-10759734-B2 | Process for the preparation and purification of misoprostol | CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS PRIVATE COMPANY LTD. (HU) | 2020-09-01 | — | — | US | disclosed |
| US-20200165186-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF MISOPROSTOL | CHINOIN PHARMACEUTICAL AND CHEMICAL WORKS PRIVATE CO. LTD. (HU) | 2020-05-28 | — | — | US | disclosed |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | TUFTS MEDICAL CENTER (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2016-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | PTGER3 1170/4885LMNA 2571/4885ABCC4 2380/4885 |
| US-10759734-B2 | Process for the preparation and purification of misoprostol | F12, VKORC1L1, SART3 | PTGER3 147/4885LMNA 1053/4885ABCC4 1081/4885 |
| US-20160052982-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | PTGER3 1170/4885LMNA 2571/4885ABCC4 2380/4885 |
| US-20200165186-A1 | PROCESS FOR THE PREPARATION AND PURIFICATION OF MISOPROSTOL | SART3, TBL3, TMSB4X | PTGER3 31/4885LMNA 787/4885ABCC4 1167/4885 |
| US-10233219-B2 | Methods and systems for designing and/or characterizing soluble lipidated ligand agents | LDLR, HDLBP, LIPG | PTGER3 1170/4885LMNA 2571/4885ABCC4 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.